Is AbbVie Inc. (ABBV) A Good Stock to Buy Now?

Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $227.68 as of March 11th. ABBV’s trailing and forward P/E were 96.07 and 15.65 respectively according to Yahoo Finance.

Copyright: mikkolem / 123RF Stock Photo

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. ABBV is navigating the post-Humira era with a diversified and growing drug portfolio, successfully transitioning from reliance on its former blockbuster. Humira, once the world’s bestselling drug with over $20 billion in annual sales, saw its U.S. patent expire in 2023 and lost protection overseas earlier, causing AbbVie’s revenue to decline temporarily.

The company, however, anticipated this eventuality and has launched a series of new therapies in immunology and oncology that are already offsetting Humira’s decline. Its immunology drugs, Skyrizi and Rinvoq, now generate combined sales of $6.9 billion, on track to surpass Humira’s peak performance, with guidance projecting $31 billion in 2027 and $40 billion by 2029. Beyond these, AbbVie’s pipeline is extensive, with 20 drugs in phase III trials and over 50 in earlier development, targeting high-demand indications such as blood cancers and Parkinson’s disease. This positions the company for sustained growth and significant future revenue streams.

Despite past headwinds from patent expirations, AbbVie’s shares have rebounded, rising over 20% in 2025, reflecting the market’s recognition of its successful transition and robust outlook. The company also combines growth with strong income, offering a $6.92 annual dividend, representing a 3.1% yield, and maintaining a 53-year history of annual dividend increases, averaging 12.5% growth over the past decade. With its de-risked revenue trajectory, expanding pipeline, and reliable cash flow, AbbVie presents an attractive investment opportunity, blending income stability with growth potential, making the stock a compelling buy for investors seeking both yield and capital appreciation.

Previously, we covered a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad in May 2025, which highlighted strong Q1 performance, Skyrizi and Rinvoq offsetting Humira’s decline, and breakthroughs in oncology with Elahere. ABBV’s stock price has appreciated by approximately 14.7% since our coverage. @MoneyShow shares a similar view but emphasizes AbbVie’s post-Humira transition, expanding pipeline, and long-term dividend growth as core investment drivers.